Lates News

On December 25th, the Japanese pharmaceutical company Daiichi Sankyo announced that its injectable trastuzumab deruxtecan (brand name: Enhertu) has received approval for a new indication in China for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low expression (IHC1+ or IHC2+/ISH-) or HER2-super low expression (IHC0 with cell membrane staining) breast cancer who have previously progressed on one or more forms of endocrine therapy in the metastatic setting, becoming the first HER2-targeted therapy for this patient population. Trastuzumab deruxtecan is a HER2-targeted antibody-drug conjugate (ADC) developed by Daiichi Sankyo using their unique DXd technology and co-developed and commercialized with AstraZeneca.